Skip to the page

Data / Federal awards / NAICS 541714 / BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL

BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL: 4 federal contract awards, $143.9 million obligated (FY2024 to FY2027)

Updated October 6, 2026. Source: USAspending.gov.

BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL (UEI UA43HWRNXFS3), Basel, Switzerland, received 4 federal prime contract awards with $143.9 million obligated in fiscal years 2024 to 2027, from 1 agency under 2 NAICS codes. Its largest buyer is Department of Health and Human Services ($143.9 million) and its largest code is NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology).

The request: Every federal contract awarded under NAICS 541714, with the winner, the agency and the value. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.

UEI
UA43HWRNXFS3
Parent organization
BASILEA PHARMACEUTICA AG
Location
Basel, Switzerland
Business size
Other Than Small Business
Contract awards
4
Obligated
$143.9 million
First action in window
2023-12-11
Latest action
2026-09-23

Where the work is

NAICS codes, with the other winners in each.

NAICSIndustryAwardsObligated
541714Research and Development in Biotechnology (except Nanobiotechnology)2$147.4 million
541711Research and Development in Biotechnology2$-3,448,555

Buying agencies

AgencyAwardsObligated
Department of Health and Human Services4$143.9 million

Obligations by fiscal year

Fiscal yearObligated
FY2024$27.5 million
FY2025$63.7 million
FY2026$52.7 million

Contract awards

All 4 awards in fiscal years 2024 to 2027.

Award IDAgencyTypeNAICSWhat it buysObligated in windowAward valueStartsEndsPlace of performanceSource
75A50124C00033Department of Health and Human ServicesDefinitive Contract541714THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA$122,501,232$122,501,232September 30, 2024March 31, 2032Switzerlandusaspending.gov
75A50123C00050Department of Health and Human ServicesDefinitive Contract541714VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.$24,870,405$45,192,122September 15, 2023December 31, 2027Malvern, PAusaspending.gov
HHSO100201300010CDepartment of Health and Human ServicesDefinitive Contract541711IGF::OT::IGF FOR OTHER FUNCTIONS THIS CONTRACT IS FOR THE CLINICAL DEVELOPMENT OF BAL30072, A NOVEL MONOSULFACTAM FOR THE TREATMENT OF INFEC$0$13,096,576June 19, 2013September 19, 2018Switzerlandusaspending.gov
HHSO100201600002CDepartment of Health and Human ServicesDefinitive Contract541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$-3,448,555$108,445,187April 19, 2016April 18, 2026Switzerlandusaspending.gov

Also on SpecStream

Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.